NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has entered into a subscription agreement to raise $500 million in gross proceeds to help fund its purchase of Life Technologies.

Under the terms of the agreement, which Thermo Fisher disclosed in a document filed with the US Securities and Exchange Commission, the company will issue in a private placement up to approximately 5.3 million shares of its common stock to Temasek at $95 per share. The share price will be adjusted depending on when the investment closes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.